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Abstract 
In this paper we study the possibility of estimating a monetary value for the QALY. 
Using two different surveys of the Spanish population (n=900), we try to establish 
whether willingness to pay (WTP) is (almost) proportional to the health gains measured 
in QALYs. We also explore whether subjects’ responses are prone to any biases. We find 
that the monetary value of the QALY is higher the smaller the health gain, pointing to 
insensitivity in WTP. We also find two clear biases. One is the existence of sequencing 
effects. The other is the insensitivity of WTP to the duration of the period of payment. All 
these effects translate into a large variation in estimates of the monetary value of the 
QALY. We conclude that in order to be able to obtain consistent and stable estimates, we 
should try to understand better the causes of these problems with a view to developing 
ways of mitigating them. 
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In recent years there has been a renewed interest in the issue of the monetary value of 
Quality Adjusted Life Years (MV-QALY). In fact, the National Institute for Health and 
Clinical Excellence (NICE) has commissioned one study in order to explore the 
possibility of estimating this figure. It is not surprising that NICE is interested in this 
research since, as Donaldson et al (2002) argue, cost-effectiveness analysis is inadequate 
in cases where a technology is both more costly and more effective. Unfortunately, as 
Neuman (2000) has shown, this is very often the case, since 80% of new medical 
technologies involve spending more money in order to achieve better health outcomes. 
Johannesson (1995) has argued that “in order to reach a decision based on cost-
effectiveness analysis, information is then needed about the willingness to pay for 
QALYs gained” (p. 485) and Johanesson and Meltzer (1998) considered that obtaining 
this information “should be a research priority” (p. 4).  
 
These authors identified two possible strategies for deriving the Willingness to Pay 
(WTP) per QALY gained. One is based on WTP for a marginal health change. The 
second strategy is to derive the WTP per QALY gained using estimates of the value of 
statistical life in the literature. 
 
Using this latter approach, Hirth (2000) estimated a WTP per QALY ranging from 
$30,000 to $430,000. More recently, Byrne et al (2005) and King et al (2005) have 
estimated much lower values, ranging from $1,200 to $32,000. Gyrd-Hansen(2003) 
estimated the MV-QALY to be 88.000 DKK (about $15,000). These three studies are the 
only ones, as far as we are aware, that had the specific objective of estimating the 
monetary value of the QALY. There have been other studies that, although they did not 
have it as their main objective to estimate WTP per QALY, have produced such a figure. 
For example, Zehraeus (1998) divided the annual WTP for hormone replacement therapy 
by the estimated QALY gain to infer a WTP per QALY of 120,000SEK (about $16,000). 
There have been other studies (Bala et al., 1998; Johnson et al, 1997) that have analyzed 
the relation between WTP and QALYs but have not provided such a figure. 
 
The study reported in this paper set out to explore the possibility of eliciting the MV-
QALY using the first strategy proposed by Johannesson and Meltzer (1998), namely, 
estimating WTP for a marginal health change.  
 
In that respect, it departs from Byrne et al and King et al who use health gains that cannot 
be considered marginal. Byrne et al focus on osteoarthritis. Although they suppose a 
relatively small drop in health status, the condition is chronic and the duration of the state 
means it cannot be considered to be a marginal health problem. Similarly, Gyrd-Hansen’s 
study involved avoiding (or improving) a chronic health problem and WTP was elicited 
as a monthly payment for the rest of their lives. Since 6 of the 11 bids used entailed a 
monthly payment of more than 200€, this cannot be considered as a marginal payment. 
King et al revolved around two health conditions (cervical spondylotic myelopathy and 
cerebral aneurysms) that cannot be considered marginal – as can be seen from the fact 








conditions. Also, their WTP was around $100,000, which can hardly be considered as 
marginal. So in this paper we want to explore the possibility of eliciting WTP for a 
QALY using marginal health gains. 
 
We acknowledge the possibility that estimating a unique MV-QALY may not be feasible. 
Several papers(Bleichrodt and Quiggin, 1999; Dolan and Edlin, 2002) have shown that 
the conditions for a unique MV-QALY to exist are quite restrictive and are unlikely to 
hold. However, our objective is more limited. As suggested by Gyrd-Hansen (2005) “one 
may take a more pragmatic stance and advocate for a ‘rule of thumb’ in determining a 
threshold for CEAs. Hence, seeking to apply a unique WTP for a QALY should not be 
seen as defining the theoretical link between CEA and CBA, but rather as an aid to 
decision-makers” (p. 428). Estimating the willingness to pay for a QALY using marginal 
health gains could be useful for decision makers if it can provide some empirical support 
to a potential cost per QALY threshold for use in regulatory decisions. Our aim is to 
explore how robust such an estimate might be. 
 
Estimating an MV-QALY using this approach does not prevent us from incorporating 
elements like a decreasing marginal valuation of health, as Johannesson and O’Connor 
(1997) suggest. For example, suppose an individual is willing to pay 2000€ for a quality 
of life gain from 0.9 to 1.0 with a duration of 1 year (0.1 QALY gain), implying an MV-
QALY of 20,000€. This does not necessarily mean that if duration is 10 years the WTP 
should be 10 times more. Abellan-Perpiñan et al (2006) or Bleichrodt and Pinto (2005) 
have suggested that a non-linear QALY model may be better than the linear model. A 
non-linear QALY model with a power coefficient for life years of 0.65 (as suggested in 
Abellan-Perpiñan et al, 2006) would imply that U(0.1, 10years) would be around 0.45 
QALYs so that WTP (setting any budget constraints aside) would be about 9.000€.  
 
Also, if one believes, as Nord et al suggest (1999) that the value of health increases with 
severity, we could estimate the relative value of health gains according to this principle. 
So if WTP is 2000€ for a one-year health gain from 0.9 to 1.0 and if the health gain from 
0.4 to 0.5 is valued twice as much, then WTP for this health gain would be 4000€, 
implying an MV-QALY of 40,000€. This approach is similar to the approach taken by 
Karnon et al (2005) in the sense that they use a “peg event for which a reliable valuation 
exists (road deaths)” in order to derive the value of life in other contexts. Our paper 
should be seen as an attempt to derive MV-QALY through a “peg event” and to explore 




2.1 Marginal health gains 
 
There are several ways of putting into practice the concept of marginal in relation to 
health gains. Basically, one can combine four factors: 
 
1. Improvement in quality of life. 








3. Gain in length of life. 
4. Change in risk. 
 
In this paper we will operationalize the concept of marginal health gains in two ways: 
 
1.  By considering health problems under certainty that, if untreated, are of short 
duration and involving a quality of life that is not too low. Of course, the concept 
of “short” and “low” is quite subjective. In general, the health gains that we will 
use will not imply more than 0.3 QALYs in the full life of a subject. In Gyrd-
Hansen (2003) there are differences in health states that are even smaller but as 
they applied to chronic health problems, the overall health gain was much larger 
than ours. 
2.  By considering chronic health problems under risk: that is, by asking WTP 
questions about treatments that reduce the (small) risk of such a health problem. 
 
2.2. Deriving Aggregate Monetary Values for a QALY 
 
Given the two measures above – WTP for small health gains under certainty, and WTP to 
reduce the risk of a large health impact – how should one proceed to estimate the social 
monetary value of a QALY? 
 
It might seem that one possible route is to estimate a value of a QALY for each 
individual respondent and then take the population average. Although we shall argue that 
this is NOT the best way to proceed, let us consider how this approach would be 
implemented. 
 
First, define the MV-QALY of respondent “i” as follows: 
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∆Q: improvement in quality of life due to the medical treatment 
t’: duration of the effect 
p*: probability of receiving the health improvement 
WTPi(∆Q, t’) = willingness to pay in order to achieve health gain for subject i. 
MV-QALYi= monetary value of the QALY for respondent i. 
 
When considering WTP for small gains under certainty, p* is set equal to 1. Thus for the 
health improvement to be marginal, we must have either ∆Q or t’ or both (very) small. 
So, for example, if ∆Q x t’ = 0.001 of a QALY and if individual i were willing to pay 30€ 
to achieve that health gain, the supposition would be that 1 QALY is worth 30,000€ to 
that individual. But this relies on one (or both) of two assumptions: either that WTP is 
strictly proportional to the duration of a given health state; or that WTP is strictly 








assumption can be said to be obviously compelling. And indeed, as we shall see, neither 
assumption is supported by the data from the study reported below. 
 
Alternatively, when considering WTP for a marginal reduction in the risk of a more 
substantial health effect, p* is small. To take the case where the health effect is death, 
research seeking to establish a value of statistical life (VSL) – sometimes also known as 
the value of preventing a (statistical) fatality (VPF) – has typically asked about WTP for 
risk reductions of the order of 10
-5. However, what is being measured here is the 
marginal rate of substitution of wealth for risk of death, and except under some very 
special assumptions (generally regarded as implausible) about the linearity of people’s 
utility function, it is not possible to infer the individual’s value of preventing his own 
certain death simply by multiplying that WTP response by 10
5, as Expression 1 might 
seem to imply.  
 
Besides the lack of theoretical justification for computing each individual’s MV-QALY 
according to Expression 1, there are also practical reasons for being wary of such a 
procedure. The very fact that the change being valued is small allows the possibility that 
responses may be susceptible to errors that may be modest in absolute terms but may be 
relatively large: for example, suppose that an individual’s ‘true’ value of reducing the risk 
of losing 1 QALY by 0.001 is actually 30€, but that uncertainty about her preferences 
means that she might on some occasions give a response as low as 10€ while on other 
occasions her response might be 50€. Multiplying these responses by the inverse of the 
risk reduction – i.e. multiplying by 1,000 – greatly magnifies the noise in the original 
response, leading to a range between 10,000€ and 50,000€.  
 
Given what we know about the difficulties people have in handling small probabilities, 
and given the greater scope for upward than downward biases (someone whose true value 
is 30€ is constrained by zero to never underestimate by more than 30€, but there is no 
such tight constraint on the potential for giving an overestimate), there is a very real 
danger that a small number of high WTP responses to the risk reduction question might 
translate into a long thin tail of outliers that may greatly inflate the mean MV-QALY. In 
the case of MV-QALYs, the danger is further aggravated by the possibility that the right-
hand tail of WTP estimates might interact with underestimates of the size of QALY gain 
afforded by a particular treatment. And as we shall see, mean values of a QALY 
estimated in this way do indeed result in much higher and more volatile estimates than 
are generated by an alternative aggregation and estimation procedure. 
 
That alternative procedure can be understood/motivated as follows. A population faces 
some chance of suffering condition X, but that chance can be reduced by treatment B. 
Providing some particular level of treatment B would, let us say, prevent/cure 10 cases of 
X. However, at the time of provision there is no way of knowing which 10 members of 
the population will benefit. All that we can work with is the overall expected size of this 
benefit in QALY terms – which we arrive at by eliciting each individual’s estimate of the 
QALY loss involved in suffering a case of X (equivalently, the QALY gain entailed by 
preventing a case of X) and taking the population mean of these estimates. If, for 








case of X constituted a loss of 2 QALYs, the total expected QALY benefit from 
providing treatment B to 10 randomly-selected members of the population would be 20 
QALYs. 
 
How much is society willing to pay for this expected QALY benefit? The answer is: the 
sum total of population members’ WTP for this level of provision of treatment B. Thus if 
treatment B were provided at this level to a population of 10,000 people, each person’s 
risk of suffering condition X would be reduced by 1 in 1000. If a representative sample 
expressed a mean WTP of 70€ for such a risk reduction, the implication is that the 
population would collectively be willing to invest 700,000€ in this programme with an 
expected benefit of 20 QALYs, giving an average figure of 35,000€ per QALY gained. 
 
For the calculation based on WTP for small but certain health gains, an analogous 
procedure would apply: First, find the mean QALY value of the small health gain, based 
on a representative sample of the population. Let us suppose for the sake of example that 
this turns out to be 0.02QALYs. To achieve a social benefit of 1 QALY would require a 
random cross-section of 50 members of the population to experience this health gain: that 
is, the total value of the gain would be 50 times the average that a representative sample 
of that population would be willing to pay for such a gain. If that average WTP were, for 





In this paper we will test two different sets of hypotheses. One set are those hypotheses 
that are needed in order to obtain a unique MV-QALY for marginal health gains. They 
are: 
 
1. MV-QALY has to be constant for any t’. 
2. MV-QALY has to be constant for any ∆Q. 
3. MV-QALY has to be constant for any p*. 
 
So the above conditions just say that WTP has to be proportional to the size of the health 
gain for marginal health gains.  
 
The second set of hypotheses test more basic rationality assumptions about WTP 
questions. They are next: 
 
4. MV-QALY has to be constant irrespective of the order of questions (no order effects). 
5. MV-QALY has to be constant irrespective of the length of the payment period.  
That is, if WTP is asked in term of monthly outlays, total WTP should not change with 













560 members of the general population were interviewed. They were distributed in 7 
subgroups according to a quota sample method (40% between 18 and 40, 30% between 
41 and 60, 30% older than 60). They were contacted by telephone through random 
dialing and those who agreed to be interviewed were visited by an interviewer. 
Sociodemographic characteristics of the sample can be seen in table 1. 
 
Table 1 Sociodemographic characteristics of the sample 














Number  subjects    80 80 80 80 80 80 80 
Gender  Women  51,3% 47,5% 50,0% 50,0% 51,3% 50,0% 51,3% 
Primary or 
less   42,5% 52,5% 45,0% 38,8% 43,8% 40,0% 47,5% 
Secondary  35,0% 32,5% 31,3% 37,5% 37,5% 36,3% 30,0% 
Educational 
Background 
University  22,5% 15,0% 23,8% 23,8% 18,8% 23,8% 22,5% 
Active  68,8% 70,0% 65,0% 76,3% 68,8% 71,3% 75,0% 
Retired  17,5% 17,5% 20,0% 18,8% 20,0% 17,5% 18,8%  Working status 
Other  13,8% 12,5% 15,0% 5,0%  11,3% 11,3% 6,3% 
<600€/month    30,0% 30,4% 31,3% 23,8% 21,3% 26,3% 20,0% 
600€  -1200€ 41,3% 43,0% 36,3% 55,0% 54,7% 40,0% 40,0% 
1200€  -1800€  21,3% 21,5% 27,5% 11,3% 20,0% 22,5% 30,0% 
Income 
>1800€  7,5% 5,1% 5,0% 10,0%  4,0% 11,3%  10,0% 
18 - 40  40,0%  41,3%  41,3%  42,5%  38,8%  42,5%  42,5% 
41 - 60  35,0%  35,0%  33,8%  32,5%  32,5%  33,8%  35,0%  Age 
>  60  25,0% 23,8% 25,0% 25,0% 28,8% 23,8% 22,5% 
 
 
3.2 Willingness to pay questions 
 
3.2.1. Health gains 
 
Each option was characterized by some combination of the following attributes: 
 
1. Quality of life. 




Each option was described as a medical treatment where one treatment implied a lower 
health outcome than the other but also a lower cost. As the less effective medical 
treatment was presented as being free at the point of consumption, one can consider this 
option to be the status quo. The framing of the question was such that the option of “no 
treatment” was not realistic. 
 










Table 2. Structure of questions 
  Treatment A Treatment B
Quality of life QA  QB 
Duration DA  DB 
Probability   PA  PB 
Cost 0  CB 
 
This structure allowed us to convey the idea of a marginal health gain. This was mainly 
achieved by using short durations or short probabilities of having the health problem. 
 
We used three Euroqol (EQ-5D) health states in order to illustrate different quality of life 
situations. EQ-5D is a standardised instrument for use as a measure of health outcome. It 
has currently 5 dimensions and 3 levels. Level 1 represents having no problems, level 2 
having moderate problems and level 3 having severe problems. One its advantages is that 
it allows to use health states where there are clear relations of dominance that can be used 
to study the consistency in people’s responses.  We used health states 21212, 22223 and 
11111. The duration of the health problems was short (4 months or 2 months) when we 
used health problems under certainty and chronic (rest of life) when the risk of the health 
problem was small (1% or 0.5%). The potential health problems presented to subjects 
were: 
 
1.  (22223, 4 months, 100% probability) 
2.  (22223, 2 months, 100% probability) 
3.  (21212, 4 months, 100% probability) 
4.  (21212, 2 months, 100% probability) 
5.  (1% risk of 22223, chronic) 
6.  (0.05% risk of 21212,chronic) 
 
The health gains used in our study are summarized in Table 3. In total, we asked WTP 









Table 3. Health improvements used in the study 
Health gain 
Treatment A  Treatment B 
Type  ∆QoL  t’ p 
(11111, 4 months)  1  22223Æ11111  4 
months  100% 
22223, 4 months 
22223, 2 months + 
11111, 2 months  2 22223Æ11111  2 
months  100% 
11111, 2 months  3  22223Æ11111  2 
months  100% 
22223, 2 months 
21212, 2 months   4  22223Æ21212  2 
months  100% 
11111, 4 months  5  21212Æ11111  4 
months  100% 
21212, 4 months 
21212, 2 months 
+11111, 2 months  6 21212Æ11111  2 
months  100% 
21212, 2 months  11111, 2 months  7  21212Æ11111  2 
months  100% 
0% risk of 
22223,chronic  8 22223Æ11111  Rest of 
life  1%  1% risk of 
22223,chronic  0.5% risk of 
22223,chronic  9 22223Æ11111  Rest of 
life  .5% 
0% risk of 
21212,chronic  10 21212Æ11111  Rest of 
life  1%  1% risk of 
21212,chronic  0.5% risk of 
21212,chronic  11 21212Æ11111  Rest of 
life  .5% 
 
3.2.2. Framing of the WTP questions 
 
For the WTP questions under certainty, subjects were asked to assume that they had been 
diagnosed with a particular illness that would, if untreated, put them in a specified health 
state (22223 or 21212) for the rest of their lives. They were told that there was a medicine 
(treatment A) which, if taken for 1 year, would cure this illness. The cost of this medicine 
for the patient was zero. They were told that it took some time for the medicine to take 
effect: 2 months in some cases, 4 months in other cases. They were also informed that 
there was another medicine (treatment B) that also cured the chronic problem but that 
was better than A. By “better” we meant one of several things: a) that it worked 
immediately, so that the lower health state (either 22223 or 21212) would not be 
experienced at all; b) that it reduced the duration of symptoms from 4 months to 2 
months; or c) it reduced the severity of the symptoms from 22223 to 21212 without 
changing the duration. They were told that none of the medicines had side effects and that 
both had to be taken for a year. However, treatment B had some monetary cost for them. 
They were then shown a visual aid of the kind reproduced in appendix 1 in order to 









For the WTP questions under risk, subjects were asked to assume that they had started 
developing some symptoms that for most people would just disappear in a few weeks. 
However, there was some chance that the symptoms might be due to an illness that, if not 
treated, was going to put them in a lower health state for the rest of their lives. The risk of 
developing this chronic illness was 1%. They were told that they could take a medicine 
that could reduce the risk, in one case from 1% to 0% and, in another case, from 1% to 
0,5%. 
 
3.3. The Questionnaire 
 
The questionnaire had four parts: 
1. Introduction 
To explain the objective of the survey and to familiarize subjects with the health states,  
they had to rate health states on a scale from 0 to 10. 
 
2. Standard Gamble 
 
We elicited utilities for health states 21212 and 22223 as chronic (rest of their lives) 
using the Standard Gamble procedure. We started asking subjects if they would accept a 
50% chance of death in order to avoid the chronic health problem. We then used a ‘ping-
pong’ method: if a subject rejected a particular level of risk, that probability was reduced 
and the question was asked again; if a subject accepted a particular level of risk, that 
probability was increased and the question was asked again. In this way, we iterated to a 
range where the indifference point was located. When this range was 5%, we asked the 
subject to give us the indifference point. For example, if the subject rejected a 5% risk but 
accepted a 10% risk we asked her to give us the indifferent point between 5% and 10%. 
In group A we also elicited the utility of 21212 with respect to health state 22223. That is, 
subjects were faced with the choice between, on the one hand, spending the rest of life in 
health state 21212, or alternatively taking a medical treatment which, if successful, would 
put them in full health but which, if it failed, would worsen their health to 22223. So in 
group A, the utility of health state 21212 was estimated directly, using an SG with death 
as the worse outcome, and also indirectly, by chaining through health state 22223. 
 
3. WTP questions 
 
The method used to elicit WTP was a card sorting procedure. The cards that were offered 
to subjects were 6€, 12€, 18€, 30€, 45€, 60€, 90€, 120€, 180€, 240€ and 300€. These 
were monthly outlays that they had to pay for 1 year, except in case of one group (labeled 
A-2) who had to pay for 2 years. The interviewer was instructed to shuffle the cards 
before them and to display all the cards on a table in a random order. Subjects were then 
asked to state the amounts that they were willing to pay, those they were not willing to 
pay and those they were not sure about. Those who said they were willing to pay all of 









4. Sociodemographic questions 
 
The interview concluded by collecting personal details of the kind reported in Table 1 
above. 
 
3.4. Hypothesis testing and Sub-groups 
 
In order to test our hypothesis we used 7 sub-groups, differentiated in order to allow our 
various hypotheses to be tested. The different WTP questions asked to each sub-group are 
shown in Table 4.  
 
Table 4 WTP questions in each sub-group and type of health gain. 
  Order 1 – large to small    Order 2 – small to large 
Group  A-1 
Group A-3 
[Type 3]   (22223,2) Æ (11111,2)  
[Type 7]   (21212,2) Æ (11111,2) 
[Type 4]   (22223,2) Æ (21212,2)  
Group  A-2 
(22223,2) Æ (21212,2) 
(21212,2) Æ (11111,2) 
(22223,2) Æ (11111,2) 
Group B-1 
[Type 1]   (22223,4) Æ (11111,4)  
[Type 5]   (21212,4) Æ (11111,4) 
[Type 2]   (22223,4) Æ[(22223,2) + (11111,2)] 
[Type 6]   (21212,4) Æ[(21212,2) + (11111,2)] 
Group B-2 
(21212,4) Æ[(21212,2) + (11111,2)] 
(22223,4) Æ[(22223,2) + (11111,2)] 
(21212,4) Æ (11111,4) 
(22223,4) Æ (11111,4) 
Group C-1 
[Type 8]   (1%, 22223) Æ (0%, 22223)  
[Type 10] (1%, 21212) Æ (0%, 21212) 
[Type 9]   (1%, 22223) Æ (0.5%, 22223)  
[Type 11] (1%, 21212) Æ (0.5%, 21212)  
Group C-2 
(1%, 21212) Æ (0.5%, 21212) 
(1%, 22223) Æ (0.5%, 22223) 
(1%, 21212) Æ (0%, 21212) 
(1%, 22223) Æ (0%, 22223) 
 
 
The 7 sub-groups can be first classified into three main blocks, that we call A, B and C. 
In each block we used two different orders when asking WTP questions. In sub-groups 
A-1, A-3, B-1 and C-1 the first question was a WTP for the largest health gain that this 
subject was going to see and the last question was a WTP question for the smallest health 
gain. On some occasions there was no objective ranking in the health gain. For example, 
in block A, it was clear that the largest health gain was health gain Type 3 [(22223, 2 
months) Æ 11111, 2] but there was not a clear ranking between health gains Type 4 and 
Type 7. In block B, it was clear that health gain Type 1 was the largest and health gain 
Type 6 was the lowest but there was not a clear ranking between health gains Type 2 and 
Type 5. The same happens with block C. Nevertheless, as far as possible we had some 
groups where the order was large to small (A-1, A-3, B-1 and C-1) while other groups 
were presented with questions in the opposite order.  
 
The only difference between A-3 and A-1 was that in group A-1 subjects were told that 
they had to pay each month for 1 year and in group A-3 for 2 years. 
 
We can test our hypotheses using these sub-groups as follows: 
 
1. MV-QALY is constant for any t’. This can be done by comparing Types 1 vs 2 and 5 








2. MV-QALY is constant for any ∆Q. This can be tested comparing all health gains 
where t’ is constant, e.g. Types 1 vs 5, 3 vs 4, 3 vs 7, 4 vs 7, 2 vs 6, 8 vs 10 and 9 vs 11. 
3. MV-QALY is constant for any p*. This can be tested comparing Types 8 vs 9 or 10 vs 
11. 
 
All these tests are within groups tests.  
 
4. MV-QALY is constant irrespective of the order of questions (no order effects). This 
can be tested by comparing the same questions for groups were the order has been 
different, that is, A-1 vs A-2, B-1 vs B-2 and C-1 vs C-2.  
5. MV-QALY is constant irrespective of the length of payment period. We will test this 




4.1. Groups A-1, A-2 and A-3 
 
Table 5 summarizes the results of groups A-1, A-2 and A-3. We can see that: 
 
1.  There are important order effects (comparison of groups A-1 and A-2). When we 
start with the lowest health gain WTP is lower. 
2.  Monthly WTP is insensitive to the period of payment (comparison of groups A-1 
and A-3). 
 
Table 5 Mean WTP per month (€) and mean utilities. In groups A-1 and A-2 the duration of payment 
was 1 year and in group A-3 it was 2 years.  
  A-1  A-2  A-3  A-1 vs A-2 A-1 vs A-3 
WTP 
        
(22223,2) Æ (11111,2)  112,32 60,13  103,61 * * 
(22223,2) Æ (21212,2)  59,65 35,48 46,9  * * 
(21212,2) Æ (11111,2)  67,55 26,38 60,93 * * 
Utilities       
State 22223  0.7026 0.7581 0.7278 ns ns 
State 21212 – direct  0.8538 0.8830 0.8608 ns ns 
State 21212 – chained  0.9353 0.9474 0.9221 ns ns 
* There are statistically significant differences at the 5% level using the t-test; 












Table 6 Median WTP per month (€) and median utilities. In groups A-1 and A-2 the duration of 
payment was 1 year and in group A-3 it was 2 years. 
  A-1 A-2 A-3 A-1  vs  A-2 A-1  vs  A-3 
WTP 
        
(22223,2) Æ (11111,2)  60 45 90 * * 
(22223,2) Æ (21212,2)  30 30 45 ns * 
(21212,2) Æ (11111,2)  45 18 55 * * 
Utilities       
State 22223  0.750 0.750 0.800 ns ns 
State 21212 – direct  0.900 0.900 0.950 ns ns 
State 21212 – chained  0.964 0.963 0.981 ns ns 
* There are statistical significant differences at the 5% level using the Mann-Whitney test. 
 
As explained earlier, the difference between U(21212)-direct and U(21212)-chained is 
that in the first case the utility of 21212 is elicited through a gamble where the outcomes 
are Full Health and Death, whereas in the second case, the utility of 21212 is elicited 
through a gamble where the outcomes are Full Health and 22223. The fact that the 
chained procedure produces higher utilities than the direct procedure is a well-known 
result in the literature (Stalmaier, 2002) and it implies that the “distance” between 22223 
and 21212 is perceived as bigger when they are compared directly than when they are 
compared through common outcomes like Full Health and Death. 
 
These results translate into the MV-QALYs reported in Table 7. As previously discussed, 
the point estimates have been calculated by combining the means of WTP responses and 
the mean health utility improvements due to a particular medical treatment. The way the 
calculation is done can be illustrated with respect to the first entry in Table 5. For Group 
A-1, the mean monthly WTP to move from 22223 to 11111 for 2 months is 112,33€. 
Multiply this by 12 to give the total WTP of 1,347.84€. This is the mean WTP for a 
health improvement worth, on average, a utility gain of 0.2974 (i.e. from 0.7026 to 1.000) 
for one-sixth of a year: that is, a QALY gain of 0.2974/6 = 0.04956. Using equation [1] 
gives MV-QALY = 27,192€. The confidence intervals have been obtained by the bias-
corrected and accelerated percentile method (Efron 1987). This approach is widely used 
in the field of health economics to estimate non-parametric bootstrap confidence intervals 
of incremental cost-effectiveness ratios (Briggs et al. 1997, Tambour and Zethraeus 1998, 
Lord and Asante 1999, Barber and Thompson 2000). The null hypothesis of equality 
between MV-QALYs can be tested checking if differences between them are equal to 
zero. Differences can be directly bootstrapped from the samples, and an approximate one-
sided significance level of the differences is obtained by calculating the proportion of 
negative values in the vector of differences (Efron and Tibshirani 1993). We will use a 
10% significance level in order to test if the MV-QALY is constant or not in all cases (for 













Table 7 Mean-based monetary value of the QALY (1,000€) in groups A-1, A-2 and A-3 
MV-QALY (1,000€)  











 (21.963-14.564)  
54.803 
(63.164-47.830) 
7a  21212, 2 months Æ 11111, 2 





63.032    
 (82.189-52.103)  
7b  21212, 2 months Æ 11111, 2 











20.454    
 (26.249-15.772)  
50.755    
 (62.773-41.954) 









The largest difference within each group is produced by the procedure used (chained or 
unchained) to elicit U(21212). Both MV-QALY elicited through the chained procedure 
are statistically different from the rest. Leaving aside the effect of chaining, the 
hypothesis that the MV-QALY is constant for any ∆Q is rejected in some but not all 
cases: the difference between the MV-QALY estimated in 3 vs 7a is statistically 
significant for groups A-1 and A-3 but not for group A-2. The difference in the MV-
QALY in 3 vs 4a is not statistically significant in any group. The difference in the MV-
QALY in 4a vs 7a is only statistically significant in group A-2. So there is mixed 
evidence concerning the effect of ∆Q on the MV-QALY.  
 
There are clearer and more unambiguous differences between groups due to order effects. 
In all cases, the MV-QALY is significantly higher in group A-1 than in A-2. Also, there 
is a large and systematic discrepancy between every MV-QALY in A-3 and its 
counterpart in A-1 and in every case we can reject at the 10% level the hypothesis that 
the MV-QALY is not influenced by length of payment period: when people have to pay 
for 2 years instead of 1 year, they hardly adjust their monthly WTP, thereby giving rise to 
a much higher MV-QALY. 
 
Although we cannot undertake comparable statistical tests, it may be of interest to see the 
corresponding estimates based on median rather than mean responses. These are shown 


















Table 7a Median-based monetary value of the QALY (1,000€) in groups A-1, A-2 and A-3 
MV-QALY (1,000€)  














7a  21212, 2 months Æ 11111, 2 





158.400    
  
7b  21212, 2 months Æ 11111, 2 
























These figures follow similar patterns (though sometimes to a more extreme extent) to 
those evident in Table 7. Only in A-2 do the values of MV-QALY look stable across 
different ∆Q (and then only when direct estimates of utility are used – the figures using 
the chained estimates appear to be much more volatile). Order effects seem a little more 
muted for 3, 4a and 4b – but somewhat more extreme for 7a and 7b. And in all cases the 
impact of payment period: on the basis of means, Group A-3 generally produced figures 
roughly double those from Group A-1; but on the basis of medians, the A-3 figures are 
between three and four times bigger than their A-1 counterparts.   
 
4.2. Groups B1, B2 
 
Results for groups B-1 and B-2 are reported in Table 8.  
 
Table 8 Mean and median WTP per month (€). Mean and median utilities 
 B1  B2  p  B1  B2  p 
WTP 
  Mean Mean   Median  Median   
(22223,4) Æ (11111,4)  156,93 78,3 *  120 47.5  + 
(21212,4) Æ (11111,4)  111,58 51,39 *  60 45  + 
(22223,4) Æ[(22223,2) + (11111,2)]  102,19 44,95 *  60 30  + 
(21212,4) Æ[(21212,2) + (11111,2)] 69,46 27,99 *  37,5 18  + 
Utilities        
State 22223  0.7198 0.6826 ns      ns 
State 21212  0.8686 0.8269 ns      + 
* There are statistically significant differences at the 5% level using the t-test. 
+ There are statistically significant differences at the 5% level using the Mann-Whitney test. 
 
These results translate to the values of  MV-QALY shown in Table 9. The hypothesis that 
MV-QALY is constant for any t’ is clearly rejected by the comparison between Types 5 








comparing Types 1 vs 5 and 2 vs 6 in both groups. As with groups A-1, A-2 and A-3 the 
existence of order effects is confirmed in groups B-1 and B-2: the MV-QALY is always 
bigger in group B-1. 
 
Table 9 Monetary value of the QALY (1,000€) in groups B-1 and B-2. 
MV-QALY (1,000€)  Health gain 
B-1 B-2 
5 21212,  4  Æ 11111, 4  30.574   
(22.716-42.695)   
10.685 
 (8.037-14.548) 




1 22223,  4  Æ 11111, 4   20.158 
(16.684-24.413) 
8.881   
(7.306-10.770) 
2 22223,  4  Æ 22223, 2 + 11111, 2  26.253   
(20.392-33.068)  
10.197   
(8.508-12.310) 
 
4.3. Groups C1 and C2  
 
We now turn to the case where risk is involved. Results are shown in Table 10.  
 
Table 10 Mean WTP per month (€) and mean utilities. Groups C-1 and C-2 
  C-1  C-2 p C-1  C-2 p 
WTP 
  Mean Mean    Median Median   
Risk reduction  Health state             
(1%Æ0%) 22223,  chronic  83.06  54.86  *  75  45  + 
(1%Æ0%) 21212,  chronic  74.10  34.95  *  60  30  + 
(1%Æ0.5%) 22223,  chronic  61.59 24.6 *  45  18  + 
(1%Æ0.5%) 21212,  chronic  39.71  16.05  *  30  12  + 
Utilities            
State 22223  0.7084 0.7040 ns 0.7  0.7  ns 
State 21212  0.8298 0.7974 ns 0.8  89  ns 
Undiscounted QALY life gain
1           
State 22223  12.23  12.29         
State 21212  7.18  8.40         











. That is, we estimated the quality adjusted life expectancy with and 
without the illness. We took the difference between these two amounts for each individual and estimated 
the mean. In order to estimate the average health gains we multiplied the undiscounted QALY gain by the 
risk reduction. E.g. the average health gain in terms of QALYs was 0.1223 for health state 22223 when the 
reduction was 1% for group C-1.  
* There are statistical significant differences at the 5% level using the t-test. 








These results translate into the MV-QALYs shown in Table 11. For example, if the 
average member of the C-1 subset is willing to pay 83.06 per month for 12 months, that 
comes to a total of 996.72. If we divide that by 0.1223 we get the MV-QALY of 8,151 
shown in the appropriate cell in Table 11. 
 
Table 11. Monetary value of the QALY.  Groups C-1 and C-2 
MV-QALY (1,000€)  Health gain 
Group C-1  Group C-2 

















The MV-QALY is higher for group C-1 than for group C-2 given the sequence effects 
observed. The hypothesis that the MV-QALY is constant for any ∆Q can be rejected only 
in one case [8 vs 10 for sub-group C-1]. The hypothesis that the MV-QALY is 
independent on the size of risk reduction can be rejected in one case [8 vs 9 for C-1].  
 
4.4. Preliminary conclusions 
 
Our hypotheses can be summarized in table 12 assuming a 10% significance level.  
 
Table 12. Summary of results for the MV-QALY. H0= MV-QALY is constant. 
Hypothesis  Comparison  Large to small  Small to large 
 1 vs 2  Reject  Reject  MV-QALY has to be constant 
for any t’  5 vs 6  Reject  Reject 
1 vs 5  Reject  Reject 
3 vs 4a   Accept  Accept 
4a vs 7a  Accept  Reject 
2 vs 6  Reject  Reject 
3 vs 7  Reject  Accept 
8 vs 10  Reject  Accept 
MV-QALY has to be constant 
for any ∆Q 
9 vs 11  Reject  Accept 
8 vs 9  Reject  Accept  MV-QALY has to be constant 
for any p*   10 vs 11  Accept  Accept 
 
 
The hypothesis that the MV-QALY is the same for any t’ is rejected: shorter durations 








∆Q is rejected in 8 of the 14 cases analyzed. When it is rejected, the MV-QALY is 
always higher when elicited through the milder health state (21212). Finally, it seems that 
we cannot reject the hypothesis that MV-QALY is constant for different risk reductions. 
 
The survey also shows a clear insensitivity to the period of payment and clear sequence 
effects. The presence of order effects is well documented in the literature (Stewart, 2002) 
on Contingent Valuation. One reaction to this problem is to assume that the less biased 
response is the first one since next questions will be influenced by the previous one(s). So 
it would be better to test our hypotheses in a between sample study where only one 
question is asked (or at least, we focus only on the first question). We then decided to 
conduct another survey aimed at testing some of our previous hypothesis in a between 
sample design. 
 
5 THE SECOND SURVEY 
 
 
5.1 Details of the survey 
 
340 members of the general population were interviewed. They were distributed in 4 
subgroups according to a quota sample method. They were contacted by telephone and 
those who agreed to be interviewed were visited by an interviewer. There were not 
statistically significant differences in sociodemographic characteristics between the four 
sub-samples. Utilities were elicited again using the SG. The framing of WTP questions 
was very similar to those asked in the previous survey. The main difference was that the 
response format was polychotomous since there were five categories of responses 
(Definitely YES/NO, Probably YES/NO, Not Sure). We will present our results using 
only the responses to the “Definitely YES” category since this is a conservative estimate 
and it has been recommended (Arrow et al, 1993) to use conservative estimates in 
Contingent Valuation studies. Also, it has been shown (Blumenschein, 2008) that 
hypothetical payments are closer to real payments when we only use the category 
“Definitely YES”. Another difference between both surveys is the number of money 
cards used: the second survey used 10€, 15€, 20€, 30€, 45€, 60€, 75€, 90€, 120€, 180€, 
300€, 450€, 600€. Subjects were asked to allocate every amount to one or other of the 
five response categories. We elicited the WTP of the following health gains: 
 
•  (22223, 4 months) Æ (11111, 4 months) 
•  (22223, 2 months) Æ (11111, 2 months) 
•  (21212, 2 months) Æ (11111, 2 months) 
•  (21212, 4 months) Æ (11111, 4 months) 
 
In this survey, no questions about risk reductions were included. Instead, we added two 










•  (22223, 2 weeks) Æ (11111, 2 weeks) 
•  (21212, 2 weeks) Æ (11111, 2 weeks) 
 
These two WTP questions were asked always as the second question, so they could have 
been influenced by the response to the first question. For this reason, the final estimate of 
the MV-QALY it is less “clean” than the other four questions. However, while 
acknowledging this potential problem, we thought that it was interesting to have some 





The results of the second survey are given in Table 13. The results of questions that were 
asked first were quite similar in both surveys. WTP for (22223, 4 months) was 157€ in 
the first survey and 163€ in the second survey. WTP for (22223, 2 months) was 112€ in 
group  A-1 and 127€ in this survey.  The differences are not statistically significant. For 
health gains that were not asked in the same order in both surveys, the results were 
different. In groups D-2 and D-4 (second survey), WTP for health gains (21212, 2 
months) and (21212, 4 months) was higher than in groups A and B, and especially higher 
than in groups A-2 and B-2. This may reflect the fact that in survey 1 the position of 
these questions was different from their position in survey 2. Once again, there was no 
sensitivity with respect to duration for health state 21212, while for health state 22223,  
WTP showed some sensitivity to duration but was not proportional.  
 










      
(22223,4) Æ (11111,4)  163.54 -------- ------  ------- 
(21212,4) Æ (11111,4)  ------  111.47 ------  ------ 
(22223,2) Æ(11111,2) ------  ------  127.37 ------ 
(21212,2) Æ(11111,2) -------  ------  ------  105.38 
(22223, 2weeks) Æ(11111,2weeks) 96.65 ------ 86.98 ----- 
(21212, 2weeks) Æ(11111,2weeks) ------ 89.72 ----- 58.88 
Utilities      
State  22223  .6412 .7010 .5627 .6752 
State  21212  .7868 .8292 .7835 .7934 
 
 
The MV-QALY is given in Table 14. There is a clear pattern here: namely, the lower the 
duration and the milder the health state, the higher is the estimate of MV-QALY. One 
particularly worrying result is that the estimates of the MV-QALY are very much larger 









Table 14. Monetary value of the QALY(€) in second survey 
 4  months 2  months  2  weeks 













More formally, the hypothesis about duration can be tested by comparing “columns” and 
the hypothesis about quality of life can be tested comparing “rows”. In almost all cases, 
the hypothesis that the monetary value of the QALY is independent of these factors can 
be rejected at the 10% significance level. The only case where it cannot be rejected is in 
the comparison of (22223. 4 months) vs (22223, 2 months). These results reinforce the 
results of survey 1, suggesting that milder health states and shorter durations both 
increase the MV-QALY estimates. The inclusion of an even shorter duration (2 weeks) 
dramatically increases the disparity. These results emerge even more strongly from the 
between-sample design of survey 2 than in survey 1, where within-subject comparisons 
may have encouraged some greater internal consistency. However, in survey 1, whenever 
there was a difference in the MV-QALY for 21212 and 22223, it was always the case that 
it was bigger when elicited through 21212 than through 22223. The results of survey 2 
reinforce concerns that the MV-QALY estimate is liable to be systematically influenced 




The main objective of this paper has been to test the robustness of the various consistency 
conditions that must hold if we are to obtain a reliable single figure for the MV-QALY 
from questions involving marginal health gains. Our results are not very encouraging 
since we find that: 
 
1. There are clear sequence effects, suggesting that responses and estimates are 
vulnerable to influences that in theory should not make a difference.  
2. The MV-QALY varies systematically with the severity of the health state used to elicit 
it, with milder health states resulting in higher estimates. 
3. The MV-QALY varies systematically with the duration of the health state used to 
elicit it, with shorter durations resulting in higher estimates. 
4. The MV-QALY can be affected dramatically by changing the duration of the period of 
payment. 
5. We find only limited evidence that different risk reductions affect the MV-QALY 
estimates. This is moderately encouraging – although it should be borne in mind that this 
result is somewhat out of line with evidence from other areas, such as the value of 
preventing road fatalities, where estimates often do vary with the size of risk reduction 










A particularly worrying result of this study is the absolute lack of sensitivity of monthly 
WTP with respect to the duration of the period of payment. Since this duration is quite 
arbitrary in many cases, the MV-QALY can be subject to manipulation by just modifying 
this parameter. This problem has nothing to do with all the assumptions that we need to 
make in order to elicit a unique MV-QALY. It is a very elementary rationality condition 
which, if not met, would undermine any serious effort to elicit these monetary values. 
Unfortunately, there is little existing evidence about this issue in the health economics 
literature. There is some more evidence on the field on environmental economics 
(Stevens, 1997; Stumborg, 2001). For example, Stumborg et al (2001) find that total 
WTP for a public good is higher when the duration of payment is 10 years than when it is 
3 years (unless a 40% discount rate is assumed). If the period of payment is arbitrary and 
the total WTP changes with it, no reliable estimates of WTP can be elicited. However, 
some others have found greater sensitivity (Johnson et al, 2006).  
 
Our study then suggests further research topics around the relationship between WTP and 
QALYs. More evidence should be collected to check whether our result that the MV-
QALY is higher for milder health states holds, and explore further the relationship 
between the duration of a health gain and WTP. Finally, we need to understand why 
WTP is not sensitive to the payment period and whether there is any way of encouraging 
the appropriate sensitivity. At present, however, we are still a long way from a situation 
where the MV-QALY can be elicited in a reliable way. 
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¾  I have some problems in 
walking about 
¾  I have some problems with self 
care 
¾  I have some problems in 
performing my usual activities 
(work, study, housework, family 
or leisure activies) 
¾  I have moderate pain or 
discomfort 
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